Cordis Consolidation Will Help J&J Save $1.6 Billion In 2008
This article was originally published in The Gray Sheet
Executive Summary
Flagging sales of Johnson & Johnson subsidiary Cordis' Cypher drug-eluting stent will require consolidation of the business and layoffs to help ensure sustained profitable growth, J&J says
You may also be interested in...
J&J Cites Economy, Increased Regulatory Costs For Large-Scale Layoffs
Johnson & Johnson will cut 6%-7% of its workforce to help shore up capital in the face of a still-struggling economy and a higher-cost regulatory environment, according to the company
J&J Cites Economy, Increased Regulatory Costs For Large-Scale Layoffs
Johnson & Johnson will cut 6%-7% of its workforce to help shore up capital in the face of a still-struggling economy and a higher-cost regulatory environment, according to the company
J&J Reshuffles Device Biz Into “Surgical” And “Comprehensive Care” Groups
Johnson & Johnson is restructuring its device and diagnostics units as part of a larger reorganization intended to improve internal collaborations and help identify opportunities beyond its existing businesses, the company says